Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 5/20 | 0.52 |
| ▸ | PSMB1 | P20618 | 4/20 | 0.52 |
| ▸ | PSMB8 | P28062 | 4/20 | 0.52 |
| ▸ | PSMB9 | P28065 | 4/20 | 0.52 |
| ▸ | PSMB10 | P40306 | 4/20 | 0.52 |
| ▸ | PSMB2 | P49721 | 4/20 | 0.52 |
| ▸ | ELANE | P08246 | 2/20 | 0.52 |
| ▸ | CTSG | P08311 | 2/20 | 0.52 |
| ▸ | CMA1 | P23946 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CNR2 | P34972 | 2/20 | 0.43 |
| ▸ | SCN10A | Q9Y5Y9 | 7/20 | 0.39 |
| ▸ | GRN | P28799 | 1/20 | 0.38 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.38 |
| ▸ | SCN2A | Q99250 | 6/20 | 0.37 |
| ▸ | CNR1 | P21554 | 2/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | LONP1 | P36776 | 4/20 | 0.36 |
| ▸ | PSMB11 | A5LHX3 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL608032 | 0.88 | ELANE (0.67) | PSMB5PSMB1PSMB8PSMB9PSMB10 | |
| SCHEMBL2933374 | 0.84 | PSMB5 (0.48) | PSMB5PSMB1PSMB8PSMB9PSMB10 | |
| SCHEMBL2932158 | 0.82 | PSMB5 (0.52) | PSMB5PSMB1PSMB8PSMB9PSMB10 | |
| SCHEMBL2927875 | 0.82 | ELANE (0.47) | PSMB5PSMB1PSMB8PSMB9PSMB10 | |
| SCHEMBL2934898 | 0.81 | CTSA (0.47) | PSMB5PSMB1PSMB8PSMB9PSMB10 | |
| SCHEMBL24195078 | 0.81 | PSMB5 (0.78) | PSMB5PSMB1PSMB8PSMB9PSMB10 | |
| SCHEMBL2933926 | 0.81 | PSMB5 (0.78) | PSMB5PSMB1PSMB8PSMB9PSMB10 | |
| SCHEMBL2930310 | 0.80 | CTSA (0.48) | PSMB5PSMB1PSMB8PSMB9PSMB10 | |
| SCHEMBL2926221 | 0.80 | GRN (0.55) | PSMB5GRNSORT1 | |
| SCHEMBL2926111 | 0.80 | HPGDS (0.53) | PSMB5PSMB1PSMB8PSMB9PSMB10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8283367-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2012-10-09 | — | — | US | claimed |
| EP-1846424-B1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2010-01-27 | — | — | EP | claimed |
| US-7468383-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2008-12-23 | — | — | US | claimed |
| EP-1846424-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2007-10-24 | — | — | EP | claimed |
| US-20060189806-A1 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2006-08-24 | — | — | US | claimed |
| WO-2006086600-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2006-08-17 | — | — | WO | claimed |
| US-8283367-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2012-10-09 | — | — | US | disclosed |
| US-20090075936-A1 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| US-7468383-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2008-12-23 | — | — | US | disclosed |
| EP-1846424-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2007-10-24 | — | — | EP | disclosed |
| US-20060189806-A1 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2006-08-24 | — | — | US | disclosed |
| WO-2006086600-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189806-A1 | Proteasome inhibitors and methods of using the same | PSMB11, PSMB5, PSMB6 | PSMB5 2/4885PSMB1 4/4885PSMB8 20/4885 |
| US-20090075936-A1 | Proteasome inhibitors and methods of using the same | PSMB11, PSMB5, PSMB6 | PSMB5 2/4885PSMB1 4/4885PSMB8 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.